Brief: Cipher Pharmaceuticals Q4 Loss Per Share $0.02 From Continuing Operations

Cipher Pharmaceuticals

19/03/2019 11:06

March 19 (Reuters) - Cipher Pharmaceuticals Inc  CPH.TO :
    * CIPHER PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR 2018
FINANCIAL RESULTS
    * Q4 LOSS PER SHARE $0.02 FROM CONTINUING OPERATIONS
    * Q4 REVENUE $6.4 MILLION VERSUS $12.1 MILLION
    * SAYS TOP LINE RESULTS FOR MOB-015 PHASE 3 STUDY IN NORTH
AMERICA
EXPECTED IN LATE Q4 2019
    * SAYS EXPECTS REGULATORY APPROVAL FOR PLECANATIDE FROM
HEALTH
CANADA IN Q4 2019
    * SAYS EXPECTS REGULATORY APPROVAL FOR A-101 FROM HEALTH
CANADA IN
Q4 2019

Source text for Eikon:  ID:nCNWycJZ9a 
Further company coverage:  CPH.TO 

 (((Reuters.Briefs@thomsonreuters.com);;))